Antifibrinolytic therapy in patients with aneurysmal subarachnoid hemorrhage. A report of the cooperative aneurysm study
H. P. Adams Jr, D. W. Nibbelink, J. C. Torner and A. L. Sahs
Antifibrinolytic therapy was used in 1,114 patients who had aneurysmal
subarachnoid hemorrhage (SAH) and who were treated by the 13 institutions
of the Cooperative Aneurysm Study. Patients were started on treatment
within one week after SAH was diagnosed, and therapy was discontinued 14
days after the ictus. Rebleeding occurred in 10% of the treated patients.
Overall mortality among the treated patients during the two weeks following
hemorrhage was 10.7%. Though some minor and a few major side effects
occurred, serious complications of therapy were infrequent.